Successful second hematopoietic cell transplantation in severe congenital neutropenia
Corresponding Author
H. Hashem
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Correspondence
Hasan Hashem, Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
Email: [email protected]
Search for more papers by this authorR. Abu-Arja
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorJ. J. Auletta
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorH. G. Rangarajan
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorE. Varga
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorM. J. Rose
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorR. P. S. Bajwa
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorCorresponding Author
H. Hashem
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Correspondence
Hasan Hashem, Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
Email: [email protected]
Search for more papers by this authorR. Abu-Arja
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorJ. J. Auletta
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorH. G. Rangarajan
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorE. Varga
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorM. J. Rose
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorR. P. S. Bajwa
Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA
Search for more papers by this authorAbstract
Allogeneic HCT is curative for SCN; however, a standard conditioning regimen or intensity has not been established. We describe a patient with SCN associated with c.1A>G (M1V) mutation in ELANE gene resulting in refractoriness to G-CSF, who received reduced-intensity HCT and developed secondary graft failure requiring a second myeloablative HCT. This case suggests that M1V mutation confers a poor G-CSF response and HCT using the best available donor is beneficial.
REFERENCES
- 1Xia J, Bolyard AA, Rodger E, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. 2009; 147: 535-542.
- 2Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med. 1989; 320: 1574-1580.
- 3Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107: 4628-4635.
- 4Rosenberg PS, Alter BP, Link DC, et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol. 2008; 140: 210-213.
- 5Setty BA, Yeager ND, Bajwa RP. Heterozygous M1V variant of ELA-2 gene mutation associated with G-CSF refractory severe congenital neutropenia. Pediatr Blood Cancer. 2011; 57: 514-515.
- 6Zeidler C, Welte K, Barak Y, Barriga F, Bolyard A. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation Peg. Blood. 2000; 95: 1195-1199.
- 7Ferry C, Ouachée M, Leblanc T, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register. Bone Marrow Transplant. 2004; 2005: 45-50.
- 8Fukano R, Nagatoshi Y, Shinkoda Y, et al. Unrelated bone marrow transplantation using a reduced-intensity conditioning regimen for the treatment of Kostmann syndrome. Bone Marrow Transplant. 2006; 38: 635-636.
- 9Thachil J, Caswell M, Bolton-Maggs PH, Pizer B, Keenan R. Non-myeloablative transplantation for severe congenital neutropenia. Pediatr Blood Cancer. 2008; 50: 920-921.
- 10Markel MK, Haut PR, Renbarger JA, Robertson KA, Goebel WS. Unrelated cord blood transplantation for severe congenital neutropenia: report of two cases with very different transplant courses. Pediatr Transplant. 2008; 12: 896-901.
- 11Oshima K, Hanada R, Kobayashi R, et al. Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: an analysis of 18 Japanese cases. Pediatr Transplant. 2010; 14: 657-663.
- 12Carlsson G, Winiarski J, Ljungman P, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer. 2011; 56: 444-451.
- 13Osone S, Imamura T, Fukushima-Nakase Y, et al. Case reports of severe congenital neutropenia treated with unrelated cord blood transplantation with reduced-intensity conditioning. J Pediatr Hematol Oncol. 2016; 38: 49-52.
- 14Nino N, Kozaki A, Hasegawa D, et al. Successful non-myeloablative allogenic bone marrow transplantation in a child with severe congenital neutropenia complicated by chronic pulmonary infection. Rinsho Ketsueki. 2016; 57: 742-747.
- 15Kawaguch K, Matsubara K, Uchida Y, et al. Successful treatment with allogenic hematopoietic stem cell transplantation of a severe congenital neutropenia patient harboring a novel ELANE mutation. Rinsho Ketsueki. 2014; 55: 2294-2299.
- 16Fioredda F, Iacobelli S, Van Biezen A, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 2016; 126: 1885-1893.
- 17Bellann-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood. 2004; 103: 4119-4125.
- 18Tidwell T, Wechsler J, Nayak RC, et al. Neutropenia-associated ELANE mutations disrupting translation initiation produce novel neutrophil elastase isoforms. Blood. 2014; 123: 562-569.
- 19Germeshausen M, Deerberg S, Peter Y, Reimer C, Kratz CP, Ballmaier M. The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia. Hum Mutat. 2013; 34: 905-914.
- 20Makaryan V, Zeidler C, Bolyard AA, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia HHS Public Access. Curr Opin Hematol. 2015; 22: 3-11.
Citing Literature
